Zogenix, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zogenix, Inc. is a pharmaceutical company primarily engaged in the development and commercialization of therapies for rare diseases, with a focus on neurological and pain disorders. The company offers a portfolio of core pharmaceutical products including FINTEPLA (fenfluramine) for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, Zogenix branded generics, and other proprietary drug candidates in clinical development. Zogenix manufactures and markets these products focused on rare epilepsy syndromes, providing therapeutic options in the fields of neurology and pain management. Founded in 2007 and headquartered in Emeryville, California, Zogenix operates primarily in the United States but also has a presence in select international markets. The company targets patients with rare epilepsy and neurological conditions through specialized pharmaceutical products and therapies. Zogenix engages in strategic collaborations and partnerships to advance its drug development pipeline and expand its commercial reach. In the last 1-2 years, Zogenix has undertaken significant operational changes including major partnerships and the expansion of its product portfolio. This includes recent strategic collaborations aimed at enhancing clinical development and commercialization efforts. The company has also invested in launching new product formulations and expanding indications for its core products, reflecting a focus on strengthening market presence and addressing unmet medical needs in rare disease sectors. Zogenix continues to evolve its business model with an emphasis on innovation and growth through acquisitions and new product launches in the rare neurological disorder space.
Needle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and Zogenix
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
Why Zogenix Flew Higher Before Leveling Off This Week
Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
Why Zogenix Stock Is on Fire Today
Why Zogenix Shares Are Soaring Today
Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021
Why Are Zogenix's Shares Gaining Today?
4 of the Fastest-Growing Stocks on the Planet Through 2024
Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q3 2021 Results - Earnings Call Transcript
Recap: Zogenix Q3 Earnings
Zogenix Reports Granting of Inducement Awards
Zogenix, Inc.: Still Cautiously Optimistic
Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy